Beta

An2 therapeutics, inc.ANTX.US Overview

US StockHealthcare
(No presentation for ANTX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ANTX AI Insights

ANTX Overall Performance

ANTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ANTX Recent Performance

-1.25%

An2 therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ANTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ANTX's Trend

ANTX Key Information

ANTX Valuation Metrics

ANTX Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Price of ANTX

ANTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ANTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.90
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.90
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ANTX's latest earnings report released?

    The most recent financial report for An2 therapeutics, inc. (ANTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANTX's short-term business performance and financial health. For the latest updates on ANTX's earnings releases, visit this page regularly.

  • How much cash does ANTX have?

    At the end of the period, An2 therapeutics, inc. (ANTX) held Total Cash and Cash Equivalents of 19.94M, accounting for 0.32 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ANTX's EPS continuing to grow?

    According to the past four quarterly reports, An2 therapeutics, inc. (ANTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ANTX?

    An2 therapeutics, inc. (ANTX)'s Free Cash Flow (FCF) for the period is -5.24M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.7% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ANTX?

    The latest valuation data shows An2 therapeutics, inc. (ANTX) has a Price-To-Earnings (PE) ratio of -5.11 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.